NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

exwannabe,

What you conveniently forget to mention, amongst other things that I have highlighted in other posts, is that there were a greater percentage of long term survivors from the original treatment group than the rGBM crossover group. This in spite of the big advantage crossover had against the rGBM control group which included a few longer term survivors compared to none known for ECAs. This coupled with evidence from outside of this trial makes this an easy pass with regulators in an orphan disease especially when looking at how this will be used in combo or with adjuvants in the clinical setting.
Message board banter is one thing but I don’t think you or anyone would want to be on a regulatory committee with the public watching and try to justify a no vote. If you think Dr. Buzdar had it bad.... whew. Just sayin!; ). Best wishes.